CRISPR–Cas9: current and future utilities in ocular diseases

Sam Yacoub; Akash Raola; Gulab Zode

doi:10.1016/B978-0-12-819291-7.00037-X

CRISPR–Cas9: current and future utilities in ocular diseases

Sam Yacoub, Akash Raola, Gulab Zode

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Genome editing consists of various technologies that involve precise modification of cellular DNA sequences. It utilizes special engineered nucleases that make specific cuts in DNA, which can result in addition, deletion, or replacement of specific nucleotides as well as modification of gene expression or induction epigenetic changes. Genome editing has been extensively used to treat various diseases, including ocular diseases, and also it is currently being utilized to study gene functions. Here, we summarize basic concepts and tools utilized in various genome editing. We further focus on recent applications of CRISPR–Cas9 in various ocular diseases.

Original language	English
Title of host publication	Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics
Publisher	Elsevier
Pages	615-623
Number of pages	9
ISBN (Electronic)	9780128192917
ISBN (Print)	9780128192924
DOIs	https://doi.org/10.1016/B978-0-12-819291-7.00037-X
State	Published - 1 Jan 2022

Keywords

CRISPR–Cas9
DNA
enzymes
Genome editing

Access to Document

10.1016/B978-0-12-819291-7.00037-X

Cite this

@inbook{8d875c10cea04b04a226dbba56418627,

title = "CRISPR–Cas9: current and future utilities in ocular diseases",

abstract = "Genome editing consists of various technologies that involve precise modification of cellular DNA sequences. It utilizes special engineered nucleases that make specific cuts in DNA, which can result in addition, deletion, or replacement of specific nucleotides as well as modification of gene expression or induction epigenetic changes. Genome editing has been extensively used to treat various diseases, including ocular diseases, and also it is currently being utilized to study gene functions. Here, we summarize basic concepts and tools utilized in various genome editing. We further focus on recent applications of CRISPR–Cas9 in various ocular diseases.",

keywords = "CRISPR–Cas9, DNA, enzymes, Genome editing",

author = "Sam Yacoub and Akash Raola and Gulab Zode",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-819291-7.00037-X",

language = "English",

isbn = "9780128192924",

pages = "615--623",

booktitle = "Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics",

publisher = "Elsevier",

}

TY - CHAP

T1 - CRISPR–Cas9

T2 - current and future utilities in ocular diseases

AU - Yacoub, Sam

AU - Raola, Akash

AU - Zode, Gulab

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Genome editing consists of various technologies that involve precise modification of cellular DNA sequences. It utilizes special engineered nucleases that make specific cuts in DNA, which can result in addition, deletion, or replacement of specific nucleotides as well as modification of gene expression or induction epigenetic changes. Genome editing has been extensively used to treat various diseases, including ocular diseases, and also it is currently being utilized to study gene functions. Here, we summarize basic concepts and tools utilized in various genome editing. We further focus on recent applications of CRISPR–Cas9 in various ocular diseases.

AB - Genome editing consists of various technologies that involve precise modification of cellular DNA sequences. It utilizes special engineered nucleases that make specific cuts in DNA, which can result in addition, deletion, or replacement of specific nucleotides as well as modification of gene expression or induction epigenetic changes. Genome editing has been extensively used to treat various diseases, including ocular diseases, and also it is currently being utilized to study gene functions. Here, we summarize basic concepts and tools utilized in various genome editing. We further focus on recent applications of CRISPR–Cas9 in various ocular diseases.

KW - CRISPR–Cas9

KW - DNA

KW - enzymes

KW - Genome editing

UR - http://www.scopus.com/inward/record.url?scp=85143307417&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-819291-7.00037-X

DO - 10.1016/B978-0-12-819291-7.00037-X

M3 - Chapter

AN - SCOPUS:85143307417

SN - 9780128192924

SP - 615

EP - 623

BT - Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics

PB - Elsevier

ER -

CRISPR–Cas9: current and future utilities in ocular diseases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this